欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2020, Vol. 25 ›› Issue (10): 1105-1110.doi: 10.12092/j.issn.1009-2501.2020.10.004

• 基础研究 • 上一篇    下一篇

舒尼替尼药代动力学和脑肾组织分布特征

陈爱瑛,程 敏,繆云萍,叶小弟,田雪君,郑高利   

  1. 浙江省神经精神疾病药物研究重点实验室,浙江省医学科学院药物研究所,杭州 310013,浙江
  • 收稿日期:2019-11-25 修回日期:2020-05-22 出版日期:2020-10-26 发布日期:2020-11-03
  • 通讯作者: 郑高利,男,博士,研究员,从事药物评价及新药开发。 Tel: 0571-88215620 E-mail: gaoli-z@163.com
  • 作者简介:陈爱瑛,女,本科,高级实验师,从事药理及药物分析。 Tel: 0571-88215620 E-mail: chay-01@163.com
  • 基金资助:
    浙江省中医药管理局资助项目(2019ZA022);浙江省神经精神疾病药物研究重点实验室资助项目(2019E10021);浙江省自然科学基金(LQ16C090001)

Pharmacokinetics and tissue distribution characteristics of sunitinib#br#

CHEN Aiying, CHENG Min, MIAO Yunping, YE Xiaodi, TIAN Xuejun, ZHENG Gaoli   

  1. Key Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, Institute of Medica Materia, Zhejing Academy of Medicine, Hangzhou 310013, Zhejiang, China
  • Received:2019-11-25 Revised:2020-05-22 Online:2020-10-26 Published:2020-11-03

摘要: 目的:建立HPLC-UV法测定大鼠血浆和小鼠组织中舒尼替尼,研究舒尼替尼在大鼠体内药代动力学和小鼠脑肾组织分布特征。方法:采用蛋白沉淀法处理血浆和组织样品,Waters XBridgeTM C18(4.6 mm×250 mm, 5 μm)色谱柱,流动相为甲醇-0.02 mol/L磷酸二氢钠(70∶30);进样量:30 μL;流速:1.0 mL/min;检测波长310 nm;柱温:25 ℃。结果: 舒尼替尼大鼠血浆浓度在0.019 2~15.34 μg/mL范围内,小鼠脑、肾组织浓度在0.038 3~11.50和0.038 3~69.00 μg/mL范围内线性关系良好。大鼠口服灌服舒尼替尼20 mg/kg,Tmax=9.0 h,Cmax=0.194 mg/L,t1/2=18.4 h,AUC(0-∞)=6.8 mg·L-1·h,绝对生物利用度为47.1%;舒尼替尼可以透过血脑屏障,但在脑组织中浓度较低,在肾组织中有较高浓度。结论:建立了大鼠血浆及小鼠组织中舒尼替尼的HPLC-UV测定方法,此方法简便、快速,结果准确可靠,为舒尼替尼的临床应用提供参考。

关键词: HPLC-UV, 舒尼替尼, 药代动力学, 组织分布, 色谱条件

Abstract: AIM: To establish a HPLC-UV method to determine sunitinib in rat plasma and mouse tissues, and to study its pharmacokinetics in rats and tissue distribution characteristics in mice.  METHODS: The biotic samples were prepared by protein precipitation followed by a stereoselective analysis of sunitinib was achieved on Waters XBridgeTM C18 (4.6 mm×250 mm, 5 μm) with a mobile phase composing of methanol-0.02 mol/L sodium dihydrogen phosphate (70∶30) at a flow rate of 1.0 mL/min. The detection wavelength was 310 nm, and the column temperature was 25 ℃. RESULTS: The calibration curve for rat plasma sunitinib was linear in the range of 0.019 2-15.34 μg/mL. The linear ranges in mice brain and kidney were 0.038 3-11.50 and 0.038 3-69.00 μg/mL, respectively. After intragastric administration of sunitinib at a dose of 20 mg/kg to rats, the pharmacokinetic characteristics were Tmax=9.0 h, Cmax=0.194 mg/L, t1/2=18.4 h, AUC(0-∞)=6.8 mg·L-1·h. And the absolute bioavailablity was 47.1%. It was indicated that sunitinib could permeate the blood brain barrier, but the concentration was lower in brain and higher in kidney. CONCLUSION: A HPLC-UV method for the determination of sunitinib in rat plasma and mouse tissues was established. The method is simple, rapid, reliable, and provides a reference for the clinical application of sunitinib.

Key words: HPLC-UV,  sunitinib, pharmacokinetics, tissue distribution, chromatographic condition

中图分类号: